by Cherry Salazar | Sep 22, 2025
Moderna, which led the biotechnology sector’s pandemic-driven surge, struggles to keep pace with the market. Moderna, Inc.’s windfall during the pandemic has now become its headwind. Once propelled to record highs by its breakthrough messenger RNA technology, the...
by Mariam Kiparoidze | Nov 27, 2023
Photo: Wikimedia Commons Covid made Pfizer a household name and sent its revenues and profits soaring. Now flush with cash and amid its post-covid slump, Pfizer is betting that its next blockbuster drug could be a cancer treatment. The pharma giant made headlines...
by Mariam Kiparoidze | Nov 3, 2023
Photo credit:Wikimedia Commons Pfizer reported a loss in the third quarter as it tries to adapt to the faltering demand on its Covid-19 drug and vaccines. Pfizer reported a net loss of $2.38 billion last quarter, missing analyst expectations, the pharmaceutical giant...
by Mariam Kiparoidze | Oct 3, 2023
Image by Mike Ramírez Mx from Pixabay Pharmaceutical giant Pfizer has teamed up with a biology biotech company Ginkgo Bioworks to research and develop RNA medicines, following a series of acquisitions and partnerships to grow and diversify its portfolio With...
by Mariam Kiparoidze | Sep 28, 2023
Even though Covid-19 cases and hospitalization numbers are up, they won’t be a shot in the arm for either Moderna or Pfizer stock. Pfizer (NYSE:PFE) closed at $32.69 per share, down by 36.2% year to date on September 22. Moderna (Nasdaq:MRNA) ended the week on a...
by Suzannah Cavanaugh | Oct 2, 2020
Moderna Inc. announced Tuesday that its Covid-19 vaccine candidate had generated levels of virus-neutralizing antibodies in older adults on par with those produced in younger trial participants, a crucial step towards approval. The early-stage result gives Moderna a...
